Divergent genomic and epigenomic landscapes of lung cancer subtypes underscore the selection of different oncogenic pathways during tumor development

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Lockwood, William W ^a,g   Wilson, Ian M ^a   Coe, Bradley P ^a   Chari, Raj ^a   Pikor, Larissa A ^a   Thu, Kelsie L ^a   Solis, Luisa M ^b   Nunez, Maria I ^b   Behrens, Carmen ^b   Yee, John ^c   English, John ^c   Murray, Nevin ^d   Tsao, Ming Sound ^e   Minna, John D ^f   Gazdar, Adi F ^f   Wistuba, Ignacio I ^b   MacAulay, Calum E ^a   Lam, Stephen ^a   Lam, Wan L ^a  

^a BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c VANCOUVER GENERAL HOSPITAL   (Canada)

^d BRITISH COLUMBIA CANCER AGENCY   (Canada)

^e UNIVERSITY HEALTH NETWORK   (Canada)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^g NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; TRANSCRIPTION FACTOR E2F1;

ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; COMPUTER MODEL; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; EPIGENETICS; FEMALE; GENE DOSAGE; GENE EXPRESSION PROFILING; GENETIC ANALYSIS; GENOMICS; HUMAN; HUMAN TISSUE; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; LUNG PARENCHYMA; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; PHENOTYPE;

ADENOCARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; EPIGENESIS, GENETIC; GENOME; HUMANS; LUNG NEOPLASMS; TRANSCRIPTOME;

EID: 84861324338     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0037775     Document Type: Article

References (96)

1. Coleman MP, Forman D, Bryant H, Butler J, Rachet B, et al. (2011) Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet 377: 127-138.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
3. Sato M, Shames DS, Gazdar AF, Minna JD, (2007) A translational view of the molecular pathogenesis of lung cancer. J Thorac Oncol 2: 327-343.
4. Giangreco A, Groot KR, Janes SM, (2007) Lung cancer and lung stem cells: strange bedfellows? Am J Respir Crit Care Med 175: 547-553.
5. Travis WD, (2002) Pathology of lung cancer. Clin Chest Med 23: 65-81, viii.
6. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, et al. (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947-957.
7. Broet P, Camilleri-Broet S, Zhang S, Alifano M, Bangarusamy D, et al. (2009) Prediction of clinical outcome in multiple lung cancer cohorts by integrative genomics: implications for chemotherapy selection. Cancer Res 69: 1055-1062.
8. Garraway LA, Sellers WR, (2006) Lineage dependency and lineage-survival oncogenes in human cancer. Nat Rev Cancer 6: 593-602.
9. Scagliotti G, Hanna N, Fossella F, Sugarman K, Blatter J, et al. (2009) The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 14: 253-263.
10. Langer CJ, Besse B, Gualberto A, Brambilla E, Soria JC, (2010) The evolving role of histology in the management of advanced non-small-cell lung cancer. J Clin Oncol 28: 5311-5320.
11. Bhattacharjee A, Richards WG, Staunton J, Li C, Monti S, et al. (2001) Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA 98: 13790-13795.
12. Thomas RK, Weir B, Meyerson M, (2006) Genomic approaches to lung cancer. Clin Cancer Res 12: 4384s-4391s.
13. Coe BP, Chari R, Lockwood WW, Lam WL, (2008) Evolving strategies for global gene expression analysis of cancer. J Cell Physiol 217: 590-597.
14. Feinberg AP, Tycko B, (2004) The history of cancer epigenetics. Nat Rev Cancer 4: 143-153.
15. Hyman E, Kauraniemi P, Hautaniemi S, Wolf M, Mousses S, et al. (2002) Impact of DNA amplification on gene expression patterns in breast cancer. Cancer Res 62: 6240-6245.
16. Pollack JR, Sorlie T, Perou CM, Rees CA, Jeffrey SS, et al. (2002) Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc Natl Acad Sci USA 99: 12963-12968.
17. Bass AJ, Watanabe H, Mermel CH, Yu S, Perner S, et al. (2009) SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet 41: 1238-1242.
18. Weir BA, Woo MS, Getz G, Perner S, Ding L, et al. (2007) Characterizing the cancer genome in lung adenocarcinoma. Nature 450: 893-898.
19. Luk C, Tsao MS, Bayani J, Shepherd F, Squire JA, (2001) Molecular cytogenetic analysis of non-small cell lung carcinoma by spectral karyotyping and comparative genomic hybridization. Cancer Genet Cytogenet 125: 87-99.
20. Pei J, Balsara BR, Li W, Litwin S, Gabrielson E, et al. (2001) Genomic imbalances in human lung adenocarcinomas and squamous cell carcinomas. Genes Chromosomes Cancer 31: 282-287.
21. Sy SM, Wong N, Lee TW, Tse G, Mok TS, et al. (2004) Distinct patterns of genetic alterations in adenocarcinoma and squamous cell carcinoma of the lung. Eur J Cancer 40: 1082-1094.
22. Tonon G, Wong KK, Maulik G, Brennan C, Feng B, et al. (2005) High-resolution genomic profiles of human lung cancer. Proc Natl Acad Sci U S A 102: 9625-9630.
23. Toyooka S, Maruyama R, Toyooka KO, McLerran D, Feng Z, et al. (2003) Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer. Int J Cancer 103: 153-160.
24. Toyooka S, Toyooka KO, Maruyama R, Virmani AK, Girard L, et al. (2001) DNA methylation profiles of lung tumors. Mol Cancer Ther 1: 61-67.
25. Sozzi G, Sard L, De Gregorio L, Marchetti A, Musso K, et al. (1997) Association between cigarette smoking and FHIT gene alterations in lung cancer. Cancer Res 57: 2121-2123.
26. Bardelli A, Cahill DP, Lederer G, Speicher MR, Kinzler KW, et al. (2001) Carcinogen-specific induction of genetic instability. Proc Natl Acad Sci U S A 98: 5770-5775.
27. Ishkanian AS, Malloff CA, Watson SK, DeLeeuw RJ, Chi B, et al. (2004) A tiling resolution DNA microarray with complete coverage of the human genome. Nat Genet 36: 299-303.
28. Jong K, Marchiori E, Meijer G, Vaart AV, Ylstra B, (2004) Breakpoint identification and smoothing of array comparative genomic hybridization data. Bioinformatics 20: 3636-3637.
29. Khojasteh M, Lam WL, Ward RK, MacAulay C, (2005) A stepwise framework for the normalization of array CGH data. BMC Bioinformatics 6: 274.
30. Coe BP, Lockwood WW, Girard L, Chari R, Macaulay C, et al. (2006) Differential disruption of cell cycle pathways in small cell and non-small cell lung cancer. Br J Cancer 94: 1927-1935.
31. Petersen I, Kotb WF, Friedrich KH, Schluns K, Bocking A, et al. (2009) Core classification of lung cancer: correlating nuclear size and mitoses with ploidy and clinicopathological parameters. Lung Cancer 65: 312-318.
32. Lockwood WW, Chari R, Coe BP, Girard L, Macaulay C, et al. (2008) DNA amplification is a ubiquitous mechanism of oncogene activation in lung and other cancers. Oncogene 27: 4615-4624.
33. Croce CM, (2008) Oncogenes and cancer. N Engl J Med 358: 502-511.
34. Doi A, Park IH, Wen B, Murakami P, Aryee MJ, et al. (2009) Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. Nat Genet 41: 1350-1353.
35. Choi SH, Worswick S, Byun HM, Shear T, Soussa JC, et al. (2009) Changes in DNA methylation of tandem DNA repeats are different from interspersed repeats in cancer. Int J Cancer 125: 723-729.
36. Hoffmann MJ, Schulz WA, (2005) Causes and consequences of DNA hypomethylation in human cancer. Biochem Cell Biol 83: 296-321.
37. Yang HH, Hu N, Wang C, Ding T, Dunn BK, et al. Influence of genetic backgroud and tissue types on global DNA methylation patterns. Plos One 5: e9355.
38. Vaissiere T, Hung RJ, Zaridze D, Moukeria A, Cuenin C, et al. (2009) Quantitative analysis of DNA methylation profiles in lung cancer identifies aberrant DNA methylation of specific genes and its association with gender and cancer risk factors. Cancer Res 69: 243-252.
39. Wu ZL, Zheng SS, Li ZM, Qiao YY, Aau MY, et al. (2009) Polycomb protein EZH2 regulates E2F1-dependent apoptosis through epigenetically modulating Bim expression. Cell Death Differ.
40. Eymin B, Gazzeri S, Brambilla C, Brambilla E, (2001) Distinct pattern of E2F1 expression in human lung tumours: E2F1 is upregulated in small cell lung carcinoma. Oncogene 20: 1678-1687.
41. Hussain M, Rao M, Humphries AE, Hong JA, Liu F, et al. (2009) Tobacco smoke induces polycomb-mediated repression of Dickkopf-1 in lung cancer cells. Cancer Res 69: 3570-3578.
42. Geradts J, Fong KM, Zimmerman PV, Minna JD, (2000) Loss of Fhit expression in non-small-cell lung cancer: correlation with molecular genetic abnormalities and clinicopathological features. Br J Cancer 82: 1191-1197.
43. Tomizawa Y, Nakajima T, Kohno T, Saito R, Yamaguchi N, et al. (1998) Clinicopathological significance of Fhit protein expression in stage I non-small cell lung carcinoma. Cancer Res 58: 5478-5483.
44. Sozzi G, Pastorino U, Moiraghi L, Tagliabue E, Pezzella F, et al. (1998) Loss of FHIT function in lung cancer and preinvasive bronchial lesions. Cancer Res 58: 5032-5037.
45. de Fraipont F, Moro-Sibilot D, Michelland S, Brambilla E, Brambilla C, et al. (2005) Promoter methylation of genes in bronchial lavages: a marker for early diagnosis of primary and relapsing non-small cell lung cancer? Lung Cancer 50: 199-209.
46. Maruyama R, Sugio K, Yoshino I, Maehara Y, Gazdar AF, (2004) Hypermethylation of FHIT as a prognostic marker in nonsmall cell lung carcinoma. Cancer 100: 1472-1477.
47. Lockwood WW, Chari R, Coe BP, Thu KL, Garnis C, et al. (2010) Integrative genomic analyses identify BRF2 as a novel lineage-specific oncogene in lung squamous cell carcinoma. PLoS Med 7: e1000315.
48. Lee ES, Son DS, Kim SH, Lee J, Jo J, et al. (2008) Prediction of recurrence-free survival in postoperative non-small cell lung cancer patients by using an integrated model of clinical information and gene expression. Clin Cancer Res 14: 7397-7404.
49. Higashiyama M, Taki T, Ieki Y, Adachi M, Huang CL, et al. (1995) Reduced motility related protein-1 (MRP-1/CD9) gene expression as a factor of poor prognosis in non-small cell lung cancer. Cancer Res 55: 6040-6044.
50. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, et al. (2006) The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313: 1929-1935.
51. Yamamoto H, Shigematsu H, Nomura M, Lockwood WW, Sato M, et al. (2008) PIK3CA mutations and copy number gains in human lung cancers. Cancer Res 68: 6913-6921.
52. Petersen I, Bujard M, Petersen S, Wolf G, Goeze A, et al. (1997) Patterns of chromosomal imbalances in adenocarcinoma and squamous cell carcinoma of the lung. Cancer Res 57: 2331-2335.
53. Dang TP, Eichenberger S, Gonzalez A, Olson S, Carbone DP, (2003) Constitutive activation of Notch3 inhibits terminal epithelial differentiation in lungs of transgenic mice. Oncogene 22: 1988-1997.
54. Wang IC, Meliton L, Tretiakova M, Costa RH, Kalinichenko VV, et al. (2008) Transgenic expression of the forkhead box M1 transcription factor induces formation of lung tumors. Oncogene 27: 4137-4149.
55. Lee DF, Kuo HP, Liu M, Chou CK, Xia W, et al. (2009) KEAP1 E3 ligase-mediated downregulation of NF-kappaB signaling by targeting IKKbeta. Mol Cell 36: 131-140.
56. Strahl BD, Allis CD, (2000) The language of covalent histone modifications. Nature 403: 41-45.
57. Esteller M, (2008) Epigenetics in cancer. N Engl J Med 358: 1148-1159.
58. Esteller M, (2007) Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 8: 286-298.
59. Barlesi F, Giaccone G, Gallegos-Ruiz MI, Loundou A, Span SW, et al. (2007) Global histone modifications predict prognosis of resected non small-cell lung cancer. J Clin Oncol 25: 4358-4364.
60. Van Den Broeck A, Brambilla E, Moro-Sibilot D, Lantuejoul S, Brambilla C, et al. (2008) Loss of histone H4K20 trimethylation occurs in preneoplasia and influences prognosis of non-small cell lung cancer. Clin Cancer Res 14: 7237-7245.
61. Lazarevich NL, Fleishman DI, (2008) Tissue-specific transcription factors in progression of epithelial tumors. Biochemistry (Mosc) 73: 573-591.
62. Grigo K, Wirsing A, Lucas B, Klein-Hitpass L, Ryffel GU, (2008) HNF4 alpha orchestrates a set of 14 genes to down-regulate cell proliferation in kidney cells. Biol Chem 389: 179-187.
63. Lazarevich NL, Cheremnova OA, Varga EV, Ovchinnikov DA, Kudrjavtseva EI, et al. (2004) Progression of HCC in mice is associated with a downregulation in the expression of hepatocyte nuclear factors. Hepatology 39: 1038-1047.
64. Lucas B, Grigo K, Erdmann S, Lausen J, Klein-Hitpass L, et al. (2005) HNF4alpha reduces proliferation of kidney cells and affects genes deregulated in renal cell carcinoma. Oncogene 24: 6418-6431.
65. Sel S, Ebert T, Ryffel GU, Drewes T, (1996) Human renal cell carcinogenesis is accompanied by a coordinate loss of the tissue specific transcription factors HNF4 alpha and HNF1 alpha. Cancer Lett 101: 205-210.
66. Watt AJ, Garrison WD, Duncan SA, (2003) HNF4: a central regulator of hepatocyte differentiation and function. Hepatology 37: 1249-1253.
67. Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, et al. (2010) Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 42: 181-185.
68. Hillemacher T, Frieling H, Moskau S, Muschler MA, Semmler A, et al. (2008) Global DNA methylation is influenced by smoking behaviour. Eur Neuropsychopharmacol 18: 295-298.
69. Kim H, Kwon YM, Kim JS, Lee H, Park JH, et al. (2004) Tumor-specific methylation in bronchial lavage for the early detection of non-small-cell lung cancer. J Clin Oncol 22: 2363-2370.
70. Kim JS, Kim H, Shim YM, Han J, Park J, et al. (2004) Aberrant methylation of the FHIT gene in chronic smokers with early stage squamous cell carcinoma of the lung. Carcinogenesis 25: 2165-2171.
71. Chari R, Lonergan KM, Ng RT, MacAulay C, Lam WL, et al. (2007) Effect of active smoking on the human bronchial epithelium transcriptome. BMC Genomics 8: 297.
72. Sun S, Schiller JH, Gazdar AF, (2007) Lung cancer in never smokers - a different disease. Nat Rev Cancer 7: 778-790.
73. Olaussen KA, Mountzios G, Soria JC, (2007) ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer. Curr Opin Pulm Med 13: 284-289.
74. Cheng L, Spitz MR, Hong WK, Wei Q, (2000) Reduced expression levels of nucleotide excision repair genes in lung cancer: a case-control analysis. Carcinogenesis 21: 1527-1530.
75. Herbst RS, Heymach JV, Lippman SM, (2008) Lung cancer. N Engl J Med 359: 1367-1380.
76. Vilmar A, Sorensen JB, (2009) Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature. Lung Cancer 64: 131-139.
77. Felip E, Rosell R, (2007) Testing for excision repair cross-complementing 1 in patients with non-small-cell lung cancer for chemotherapy response. Expert Rev Mol Diagn 7: 261-268.
78. Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, et al. (2006) DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355: 983-991.
79. Gollob JA, Wilhelm S, Carter C, Kelley SL, (2006) Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin Oncol 33: 392-406.
80. Guo NL, Wan YW, Tosun K, Lin H, Msiska Z, et al. (2008) Confirmation of gene expression-based prediction of survival in non-small cell lung cancer. Clin Cancer Res 14: 8213-8220.
81. Zhao Y, Tan J, Zhuang L, Jiang X, Liu ET, et al. (2005) Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim. Proc Natl Acad Sci U S A 102: 16090-16095.
82. Orzan F, Pellegatta S, Poliani L, Pisati F, Caldera V, et al. (2010) Enhancer of Zeste 2 (Ezh2) Is up-Regulated in Malignant Gliomas and in Glioma Stem-Like Cells. Neuropathol Appl Neurobiol.
83. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, et al. (2011) International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 6: 244-285.
84. Wilkerson MD, Yin X, Hoadley KA, Liu Y, Hayward MC, et al. (2010) Lung squamous cell carcinoma mRNA expression subtypes are reproducible, clinically important, and correspond to normal cell types. Clin Cancer Res 16: 4864-4875.
85. Garraway LA, Sellers WR, (2006) From integrated genomics to tumor lineage dependency. Cancer Res 66: 2506-2508.
86. Garnis C, Davies JJ, Buys TP, Tsao MS, MacAulay C, et al. (2005) Chromosome 5p aberrations are early events in lung cancer: implication of glial cell line-derived neurotrophic factor in disease progression. Oncogene 24: 4806-4812.
87. Baldwin C, Garnis C, Zhang L, Rosin MP, Lam WL, (2005) Multiple microalterations detected at high frequency in oral cancer. Cancer Res 65: 7561-7567.
88. Lockwood WW, Coe BP, Williams AC, MacAulay C, Lam WL, (2007) Whole genome tiling path array CGH analysis of segmental copy number alterations in cervical cancer cell lines. Int J Cancer 120: 436-443.
89. Watson SK, Deleeuw RJ, Ishkanian AS, Malloff CA, Lam WL, (2004) Methods for high throughput validation of amplified fragment pools of BAC DNA for constructing high resolution CGH arrays. BMC Genomics 5: 6.
90. Chi B, DeLeeuw RJ, Coe BP, MacAulay C, Lam WL, (2004) SeeGH - A software tool for visualization of whole genome array comparative genomic hybridization data. BMC Bioinformatics 5: 13.
91. Chi B, deLeeuw RJ, Coe BP, Ng RT, MacAulay C, et al. (2008) MD-SeeGH: a platform for integrative analysis of multi-dimensional genomic data. BMC Bioinformatics 9: 243.
92. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, et al. (2003) Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4: 249-264.
93. Bild AH, Yao G, Chang JT, Wang Q, Potti A, et al. (2006) Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439: 353-357.
94. Travis WD, Brambilla E, Muller-Hemelink HK, Harris CC, (2004) World Health Organization Classification of tumours. In: Pathology and Genetics of Tumous of the Lung, Pleura, Thymus, WD Heart;Travis, editors. editor Lyon IARC Press.
95. Solis LM, Behrens C, Dong W, Suraokar M, Ozburn NC, et al. (2010) Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features. Clin Cancer Res 16: 3743-3753.
96. Yuan P, Kadara H, Behrens C, Tang X, Woods D, et al. (2010) Sex determining region Y-Box 2 (SOX2) is a potential cell-lineage gene highly expressed in the pathogenesis of squamous cell carcinomas of the lung. PLoS One 5: e9112.